Mobile-Based Application "MyChoices"
Mobile-Based Application "MyChoices" to Increase Uptake of HIV Testing, Detection of New HIV Infections, and Linkage to Care and Prevention Services by Young Men Who Have Sex With Men
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
"MyChoices", an app adapted from HealthMindr and developed using iterative feedback from youth, is being refined to to maximize acceptability among YMSM. "MyChoices" was guided by the Social Cognitive Theory (SCT) model and includes three major functions that are designed to promote self-efficacy, self-regulation, goal-setting and environmental influences in order to impact behavior change. (1) Tracking and Self-Monitoring HIV Risk: In order to target self-regulation, brief surveys within the app are used to assess behavioral patterns of YMSM, particularly around sexual relationships, which are then used to help customize the app for each user. (2) HIV and sexually transmitted infection (STI) Prevention Information: In order to improve self-efficacy for HIV testing and HIV prevention overall, quizzes and infographics that appeal to YMSM have been incorporated into the app, focusing on promotion of HIV prevention and regular HIV testing. The app also allows users to order OraQuick HIV home testing kits and STI home collection kits (for rectal and urethral gonorrhea and Chlamydia and syphilis). Additionally, the app includes information on testing sites and local PrEP clinics (e.g., telephone, address, hours of testing, etc), and external links to specific site webpages that are near the user (determined using GPS technology). (3) HIV Testing Plan: Acknowledging the central role of goal setting and environmental influences on health behavior, the app allows users to create a HIV testing plan by allowing them to compare and choose different screening options (e.g., home self-testing, antigen, rapid). Questions about HIV transmission behaviors and testing history are then asked to create a tailored testing plan. After a HIV testing plan is developed, users have the option to customize reminders for the timeframe selected (e.g., user is pinged every 3 months as a reminder to get tested). Users are able to select from a list of phrases or create their own to ensure privacy. Moreover, geofencing technology allows users to be notified when in the vicinity of testing locations, based on the Geo Positioning System (GPS) location, during the testing timeframe.
This study is part of the iTech NIH U19, which has an overall goal to develop innovative technology-focused interventions addressing the HIV prevention and care continuum for youth.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Fenway Health Center
-
-
New York
-
Bronx, New York, Stati Uniti, 10467
- Montefiore Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- No HIV test in the past 3 months (self-reported).
- Not known to be HIV-infected (self-reported).
- Not currently taking PrEP (self-report).
- Owns or leases a phone with Android platform (for Aims 2 and 3) or iOS platform (Aim 3 only), has an active data plan, and willing to download the MyChoices application.
- Willing to attend an in-person baseline study visit in Boston or the Bronx and complete online follow-up visits.
- Able to understand, read, and speak English.
- Participants ages 15-18: self-report at least one episode of anal intercourse with a male or transfemale partner during the last 6 months.
Participants ages 19-24: self-report evidence of high risk for acquiring HIV infection including at least one of the following:
- at least one episode of condomless anal intercourse with an HIV-infected or unknown HIV status male or transfemale partner during the last 6 months; or
- anal intercourse with 2 or more male or transfemale sex partners during the last 6 months; or
- exchange of money, gifts, shelter, or drugs for anal sex with a male or transfemale partner during the last 6 months; or
- sex with a male or transfemale partner and has had an STI during the last 6 months.
Exclusion Criteria:
- Any health condition that may interfere with participation or the ability to provide informed consent, including any debilitating or life-threatening conditions.
- Prior enrollment in an HIV vaccine trial with receipt of experimental vaccine product and evidence of vaccine-induced seropositivity.
- Known to be HIV-infected.
- Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: MyChoices
Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
|
Accesso all'app mobile MyChoices che include il piano di test HIV con promemoria, informazioni sulle IST, risorse PrEP, collegamenti a siti di test e PrEP e funzionalità di geolocalizzazione.
|
|
Nessun intervento: Standard of Care
Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Acceptability: System Usability Scale
Lasso di tempo: 3 months
|
System Usability Scale: a validated scale that assesses subjective usability of a system, or, in this case, an app.
The System Usability Scale consists of a 10 item questionnaire with five response options; from Strongly agree to Strongly disagree.
The items scores are converted into a score from 0 (negative) to 100 (positive).
A score of ≥50 indicates that the app is acceptable, and a score above 68 is considered above average.
|
3 months
|
|
Feasibility: Frequency of Logins
Lasso di tempo: 3 months
|
Number of individuals who logged into app at least one time after set up
|
3 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Preliminary Efficacy: Number of Participants Self-reported Having Tested for HIV
Lasso di tempo: 6 months
|
Self-report having tested for HIV over follow up
|
6 months
|
|
Preliminary Efficacy: Number of Participants Self-reported Having Initiated PrEP
Lasso di tempo: 6 months
|
Self-report of participants reporting PrEP initiation anytime over study follow up
|
6 months
|
|
Number of Times Participants Used Distinct App Components
Lasso di tempo: 3 months
|
The total number of times that participants selected distinct components (e.g., testing plan, ordering, FAQs) of the app were summed
|
3 months
|
|
App Content and Functionality Most Utilized
Lasso di tempo: 3 months
|
We a priori identified the primary app components (i.e., HIV test plan, location search, ordering supplies, FAQs) and report the number of participants using these app components at least once over follow up
|
3 months
|
|
Number of HIV Home Testing Kits Ordered
Lasso di tempo: 6 months
|
Number of Participants who ordered at least one HIV home testing kit over follow up
|
6 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Katie B Biello, PhD, MPH, Protocol Co-Chair, Research Study MPI
- Investigatore principale: Kenneth H Mayer, MD, Fenway Health Center
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 1U19HD089881 (SubProject 8784)
- 1U19HD089881 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .